Based on the Sartorius Stedim Biotech S.A stock forecast from 0 analysts, the average analyst target price for Sartorius Stedim Biotech S.A is not available over the next 12 months. Sartorius Stedim Biotech S.A’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Sartorius Stedim Biotech S.A is Slightly Bearish, which is based on 5 positive signals and 9 negative signals. At the last closing, Sartorius Stedim Biotech S.A’s stock price was USD 195.00. Sartorius Stedim Biotech S.A’s stock price has changed by -2.11% over the past week, +10.73% over the past month and -28.83% over the last year.
No recent analyst target price found for Sartorius Stedim Biotech S.A
No recent average analyst rating found for Sartorius Stedim Biotech S.A
Company Overview Sartorius Stedim Biotech S.A
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG. Read Less
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for ...Read More
Frequently Asked Questions About Sartorius Stedim Biotech S.A (SDMHF) Stock
Stock Target Advisor's fundamental analysis for Sartorius Stedim Biotech S.A's stock is Slightly Bearish.
SDMHF stock's dividend yield is 0.38%.
Our analysis grades SDMHF stock's dividend yield at F. This means that SDMHF stock's dividend yield is above 14% of the stocks in the Medical Instruments & Supplies sector in the OTC exchange.
Based on this SDMHF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on SDMHF's stock to indicate what its average analyst target is.
SDMHF stock's Price/Earning ratio is 113.83.
Our analysis grades SDMHF stock's Price / Earning ratio at F. This means that SDMHF stock's Price/Earning ratio is above 79% of the stocks in the Medical Instruments & Supplies sector in the OTC exchange.
Based on this SDMHF may be a overvalued for its sector.
The last closing price of SDMHF's stock was USD 195.00.
The most recent market capitalization for SDMHF is USD 19.90B.
Unfortunately we do not have enough analyst data on SDMHF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sartorius Stedim Biotech S.A's stock.
As per our most recent records Sartorius Stedim Biotech S.A has 10,082 Employees.
Sartorius Stedim Biotech S.A's registered address is Zone Industrielle Les Paluds, Aubagne, France, 13781.
You can get more information about it from Sartorius Stedim Biotech S.A's website at https://www.sartorius.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Sartorius Stedim Biotech S.A (SDMHF) Stock
Stock Target Advisor's fundamental analysis for Sartorius Stedim Biotech S.A's stock is Slightly Bearish.
SDMHF stock's dividend yield is 0.38%.
Our analysis grades SDMHF stock's dividend yield at F. This means that SDMHF stock's dividend yield is above 14% of the stocks in the Medical Instruments & Supplies sector in the OTC exchange.
Based on this SDMHF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on SDMHF's stock to indicate what its average analyst target is.
SDMHF stock's Price/Earning ratio is 113.83.
Our analysis grades SDMHF stock's Price / Earning ratio at F. This means that SDMHF stock's Price/Earning ratio is above 79% of the stocks in the Medical Instruments & Supplies sector in the OTC exchange.
Based on this SDMHF may be a overvalued for its sector.
The last closing price of SDMHF's stock was USD 195.00.
The most recent market capitalization for SDMHF is USD 19.90B.
Unfortunately we do not have enough analyst data on SDMHF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sartorius Stedim Biotech S.A's stock.
As per our most recent records Sartorius Stedim Biotech S.A has 10,082 Employees.
Sartorius Stedim Biotech S.A's registered address is Zone Industrielle Les Paluds, Aubagne, France, 13781.
You can get more information about it from Sartorius Stedim Biotech S.A's website at https://www.sartorius.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SDMHF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
